CN102316892A - 心肌营养素-1用于治疗代谢病的用途 - Google Patents
心肌营养素-1用于治疗代谢病的用途 Download PDFInfo
- Publication number
- CN102316892A CN102316892A CN2010800092569A CN201080009256A CN102316892A CN 102316892 A CN102316892 A CN 102316892A CN 2010800092569 A CN2010800092569 A CN 2010800092569A CN 201080009256 A CN201080009256 A CN 201080009256A CN 102316892 A CN102316892 A CN 102316892A
- Authority
- CN
- China
- Prior art keywords
- insulin
- plain
- chemical compound
- myocardial nutrition
- variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/204—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (15)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200900396 | 2009-02-12 | ||
ESP200900396 | 2009-02-12 | ||
PCT/ES2010/070072 WO2010092218A2 (es) | 2009-02-12 | 2010-02-10 | Uso de la cardiotrofina-1 para el tratamiento de enfermedades metabólicas |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102316892A true CN102316892A (zh) | 2012-01-11 |
CN102316892B CN102316892B (zh) | 2014-06-04 |
Family
ID=42562119
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201080009256.9A Expired - Fee Related CN102316892B (zh) | 2009-02-12 | 2010-02-10 | 心肌营养素-1用于治疗代谢病的用途 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20110293562A1 (zh) |
EP (1) | EP2397152B1 (zh) |
JP (1) | JP2012517459A (zh) |
CN (1) | CN102316892B (zh) |
AU (1) | AU2010212794A1 (zh) |
BR (1) | BRPI1008415A2 (zh) |
CA (1) | CA2750074A1 (zh) |
ES (1) | ES2493618T3 (zh) |
MX (1) | MX2011008562A (zh) |
RU (1) | RU2011137413A (zh) |
WO (1) | WO2010092218A2 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11419916B2 (en) | 2012-09-11 | 2022-08-23 | Energesis Pharmaceuticals, Inc. | Methods and compositions for inducing differentiation of human brown adipocyte progenitors |
US10405961B2 (en) | 2013-03-14 | 2019-09-10 | Cell and Molecular Tissue Engineering, LLC | Coated surgical mesh, and corresponding systems and methods |
US10130288B2 (en) | 2013-03-14 | 2018-11-20 | Cell and Molecular Tissue Engineering, LLC | Coated sensors, and corresponding systems and methods |
CN106255748A (zh) * | 2014-02-24 | 2016-12-21 | 释放能量医药股份有限公司 | 诱导人褐色脂肪细胞祖细胞分化的方法和组合物 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL68769A (en) | 1983-05-23 | 1986-02-28 | Hadassah Med Org | Pharmaceutical compositions containing insulin for oral administration |
US4849405A (en) | 1984-05-09 | 1989-07-18 | Synthetic Blood Corporation | Oral insulin and a method of making the same |
WO1985005029A1 (en) | 1984-05-09 | 1985-11-21 | Medaphore Inc. | Oral insulin and a method of making the same |
US4963526A (en) | 1984-05-09 | 1990-10-16 | Synthetic Blood Corporation | Oral insulin and a method of making the same |
US5614492A (en) | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
US4992417A (en) | 1987-07-17 | 1991-02-12 | Mount Sinai School Of Medicine | Superactive human insulin analogues |
US5514646A (en) | 1989-02-09 | 1996-05-07 | Chance; Ronald E. | Insulin analogs modified at position 29 of the B chain |
US5642868A (en) | 1990-05-02 | 1997-07-01 | The United States Of America As Represented By The Secretary Of The Navy | Ceramic material |
IL99699A (en) | 1990-10-10 | 2002-04-21 | Autoimmune Inc | Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes |
US5672659A (en) | 1993-01-06 | 1997-09-30 | Kinerton Limited | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
US6191105B1 (en) | 1993-05-10 | 2001-02-20 | Protein Delivery, Inc. | Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin |
US5474978A (en) | 1994-06-16 | 1995-12-12 | Eli Lilly And Company | Insulin analog formulations |
US5461031A (en) | 1994-06-16 | 1995-10-24 | Eli Lilly And Company | Monomeric insulin analog formulations |
US5595760A (en) | 1994-09-02 | 1997-01-21 | Delab | Sustained release of peptides from pharmaceutical compositions |
US5547929A (en) | 1994-09-12 | 1996-08-20 | Eli Lilly And Company | Insulin analog formulations |
US5693609A (en) | 1994-11-17 | 1997-12-02 | Eli Lilly And Company | Acylated insulin analogs |
US5843866A (en) | 1994-12-30 | 1998-12-01 | Hampshire Chemical Corp. | Pesticidal compositions comprising solutions of polyurea and/or polyurethane |
YU18596A (sh) | 1995-03-31 | 1998-07-10 | Eli Lilly And Company | Analogne formulacije monomernog insulina |
US5824638A (en) | 1995-05-22 | 1998-10-20 | Shire Laboratories, Inc. | Oral insulin delivery |
US5665702A (en) | 1995-06-06 | 1997-09-09 | Biomeasure Incorporated | Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides |
US5916883A (en) | 1996-11-01 | 1999-06-29 | Poly-Med, Inc. | Acylated cyclodextrin derivatives |
US6153632A (en) | 1997-02-24 | 2000-11-28 | Rieveley; Robert B. | Method and composition for the treatment of diabetes |
PE79099A1 (es) | 1997-06-13 | 1999-08-24 | Lilly Co Eli | Formulaciones de insulina estables |
IL137388A (en) | 1998-01-29 | 2005-05-17 | Poly Med Inc | Absorbable microparticles |
EP1306091A3 (en) | 1998-07-31 | 2003-05-21 | Novo Nordisk A/S | Stimulation of beta cell proliferation |
US6211144B1 (en) | 1998-10-16 | 2001-04-03 | Novo Nordisk A/S | Stable concentrated insulin preparations for pulmonary delivery |
US20040110287A1 (en) * | 2002-07-29 | 2004-06-10 | Es Cell International Pte Ltd. | Multi-step method for the differentiation of insulin positive, glucose responsive cells |
WO2005053728A2 (de) * | 2003-12-01 | 2005-06-16 | Xantos Biomedicine Ag | Mit adipositas assoziierte proteine und deren verwendung in therapie und diagnostik |
GT200600046A (es) * | 2005-02-09 | 2006-09-25 | Terapia de combinacion | |
JP2008533101A (ja) * | 2005-03-17 | 2008-08-21 | ノボ ノルディスク アクティーゼルスカブ | 肥満の治療において使用するための化合物 |
KR20080095879A (ko) | 2006-02-15 | 2008-10-29 | 사노피-아벤티스 | 신규 아자사이클릴-치환된 아릴티에노피리미디논, 이의 제조 방법 및 이의 약물로서의 용도 |
-
2010
- 2010-02-10 CN CN201080009256.9A patent/CN102316892B/zh not_active Expired - Fee Related
- 2010-02-10 JP JP2011549615A patent/JP2012517459A/ja active Pending
- 2010-02-10 BR BRPI1008415-0A patent/BRPI1008415A2/pt not_active IP Right Cessation
- 2010-02-10 ES ES10710061.2T patent/ES2493618T3/es active Active
- 2010-02-10 AU AU2010212794A patent/AU2010212794A1/en not_active Abandoned
- 2010-02-10 CA CA2750074A patent/CA2750074A1/en not_active Abandoned
- 2010-02-10 WO PCT/ES2010/070072 patent/WO2010092218A2/es active Application Filing
- 2010-02-10 US US13/201,431 patent/US20110293562A1/en not_active Abandoned
- 2010-02-10 RU RU2011137413/15A patent/RU2011137413A/ru unknown
- 2010-02-10 EP EP10710061.2A patent/EP2397152B1/en active Active
- 2010-02-10 MX MX2011008562A patent/MX2011008562A/es not_active Application Discontinuation
Non-Patent Citations (3)
Title |
---|
B.MACROS-GOMEZ ET AL.,: ""Obesity, inflammation and insulin resistance:role of gp 130 receptor ligands"", 《AN SIST SANIT NAVAR》 * |
MARK A.FEBBRAIO: ""gp130 receptor ligands as potential therapeutic targets for obesity"", 《JOURNAL OF CLINICAL INVESTIGATION》 * |
SANJIN ZVONIC ET AL.,: ""Effects of Cardiotrophin on Adipocytes"", 《THE JOURNAL OF BIOLOGICAL CHEMISTRY》 * |
Also Published As
Publication number | Publication date |
---|---|
EP2397152A2 (en) | 2011-12-21 |
MX2011008562A (es) | 2011-09-09 |
WO2010092218A3 (es) | 2010-11-18 |
WO2010092218A2 (es) | 2010-08-19 |
RU2011137413A (ru) | 2013-03-20 |
CN102316892B (zh) | 2014-06-04 |
CA2750074A1 (en) | 2010-08-19 |
EP2397152B1 (en) | 2014-05-28 |
JP2012517459A (ja) | 2012-08-02 |
BRPI1008415A2 (pt) | 2018-02-27 |
US20110293562A1 (en) | 2011-12-01 |
AU2010212794A1 (en) | 2011-08-11 |
ES2493618T3 (es) | 2014-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103491975B (zh) | 酰化胰高血糖素类似物与胰岛素类似物的组合 | |
Vanhorebeek et al. | Glycemic and nonglycemic effects of insulin: how do they contribute to a better outcome of critical illness? | |
JP5114381B2 (ja) | 精神疾患および障害治療用アミリンおよびアミリンアゴニスト | |
CN100528222C (zh) | 共聚物-1在制备治疗多发性硬化症的口服固体药物中的用途 | |
WO2007112069A2 (en) | Endothelin and endothelin receptor agonists in the treatment of metabolic diseases | |
CN102316892B (zh) | 心肌营养素-1用于治疗代谢病的用途 | |
Palin et al. | The type 1 TNF receptor and its associated adapter protein, FAN, are required for TNFα-induced sickness behavior | |
ES2818556T3 (es) | Péptido con eficacia antiobesidad y antidiabética y uso del mismo | |
Chen et al. | Intracisternal urocortin inhibits vagally stimulated gastric motility in rats: role of CRF2 | |
Prasathkumar et al. | Evaluation of hypoglycemic therapeutics and nutritional supplementation for type 2 diabetes mellitus management: an insight on molecular approaches | |
EP3845550B1 (en) | Composition for accelerating cell proliferation comprising erythropoietin-derived peptide | |
CN118028156A (zh) | 一株具有降糖减脂功效的侧孢短芽孢杆菌及其应用 | |
Haas et al. | Peripheral but not central leptin treatment increases numbers of circulating NK cells, granulocytes and specific monocyte subpopulations in non-endotoxaemic lean and obese LEW-rats | |
CN112891540A (zh) | Ogt作为靶点在制备治疗糖尿病中胰高血糖素异常分泌的药物中的应用 | |
KR20200096449A (ko) | Fas 신호전달 억제용 펩티드를 포함하는 비만, 지방간 또는 지방간염의 예방 또는 치료용 약학적 조성물 | |
Hirschberg | Effects of growth hormone and IGF-I on glomerular ultrafiltration in growth hormone-deficient rats | |
CN112138148B (zh) | 一种生长激素或其类似物的口服药物组合物 | |
CN112587545A (zh) | 枸杞多糖在制备舒张胸主动脉药物中的用途 | |
CN114129711A (zh) | 度拉糖肽在制备抗肿瘤药物中的应用 | |
CN102462662A (zh) | 脂质体包裹重组人睫状神经营养因子 | |
US20200000884A1 (en) | Treatment of adult growth hormone deficiency with human growth hormone analogues | |
Chen et al. | An overview of hypoglycemic biological drugs | |
CN101670098B (zh) | 重组人胸腺素α原在制备预防及治疗脂肪肝药物中的应用 | |
Edelman et al. | Amylin replacement therapy in patients with type 1 diabetes | |
KR102389898B1 (ko) | Fgf11 발현을 억제하는 제제를 포함하는 대사질환 예방 또는 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: UNIVERSIDAD DE NAVARRA Free format text: FORMER OWNER: INSTITUTO CIENTIFICO Y TECNOLOGICO DE NAVARRA S A Effective date: 20130320 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20130320 Address after: Navarra Spain Applicant after: Proyecto Biomedicina Cima Sl Applicant after: UNIV DE NAVARRA Address before: Navarra Spain Applicant before: Proyecto Biomedicina Cima Sl Applicant before: Instituto Cientifico Y Tecnologico De Navarra S A |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140604 Termination date: 20150210 |
|
EXPY | Termination of patent right or utility model |